GE HealthCare today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

A new EMA approval has expanded the use of Vertex Pharma’s cystic fibrosis therapy ... including Denmark and Ireland. "Today’s approval brings us closer to our ultimate goal of providing ...

Sphere Fluidics, a leading provider of innovative picodroplet-based microfluidics solutions for functional single cell analysis and isolation, today announced the launch of Cyto-Mine® Chroma and the ...

AstraZeneca suggested earlier this year that one reason for a decision to site a new facility in Ireland ... with the Association of the British Pharmaceutical Industry (ABPI) calling the MHRA ...

Citing examples from Ireland and Thailand, the Survey noted that excessive ... The drug, suzetrigine, will be sold under the brand name Journavx, and manufactured by US-based Vertex Pharmaceuticals.

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

Reports Q4 revenue $2.91B, consensus $2.78B. “2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another ...

For the full year, Vertex guided for revenue between $11.75 billion and $12 billion, which includes the U.S. launch of cystic fibrosis treatment for patients aged six and older Alyftrek and early ...